Arbeitsgruppe Molekulare Psychiatrie (Prof. Dr. Thomas Bayer)

UNIVERSITÄTSMEDIZIN GÖTTINGEN, Klinik für Psychiatrie und Psychotherapie

Developing an Alzheimer drug

 

MBM ScienceBridge GmbH, Georg-August-University Göttingen, University Medical Center (UMG) and MRC Technology (2017 renamed in LifeArc), a UK medical research charity, are collaborating on new therapy for neurodegenerative diseases.

MBM ScienceBridge GmbH, Georg-August-University Göttingen, University Medical Center and LifeArc, a UK medical research charity, have signed an exclusive license agreements for the development of a novel therapy of neurodegenerative diseases based on antibody targeting N-truncated amyloid beta peptides. The aim is to develop a therapy for Alzheimer's Disease (AD).

The licence negotiated by MBM ScienceBridge GmbH, the technology transfer organization of the Georg-August-Universität Göttingen, will enable UMG to access the world-class antibody humanization expertise of LifeArc’s Centre for Therapeutics Discovery and the work of its Therapeutic Antibody Group, led by Dr David Matthews and gives LifeArc the opportunity to use its renowned capability to take lab tool compounds and turn them into clinical candidates, which will then be licensed to the pharmaceutical and biotech industry.

LifeArc receives an exclusive worldwide license to the IP rights of UMG related to a novel therapeutic approach for the treatment of sporadic and familial AD, based on a panel of unique antibodies developed by its scientist Prof. Dr. Thomas Bayer. LifeArc and UMG will then receive downstream payments dependent on the successful development and out-licensing of the antibody. This income will be used for further research within the organisations.